Tzvia Bader Discusses the TrialJectory Platform Connecting Patients With Cancer to Clinical Trials

Article

CancerNetwork® spoke with Tzvia Bader about barriers between patients and appropriate clinical trials and how to combat these issues.

CancerNetwork® sat down with Tzvia Bader, CEO and co-founder of TrialJectory, to discuss the artificial intelligence-powered platform that helps match patients with cancer to appropriate clinical trials.

Bader said that patients who take a proactive role in their treatment, what she terms “activated patients,” are becoming more common in health care today, especially with greater access to information. As a result, patients are taking a more active role in every level of care, from decision making to research regarding viable treatment options. She explains that certain aspects of choosing appropriate therapy, such as individual levels of pain tolerance and the ability to accommodate numerous out-patient visits, is known best by the patients themselves.

In addition, Bader said TrialJectory will help lower barriers to inclusion of a more diverse patient population in clinical trials.

“How can we expect diversity when 85% of patients are being treated in the community setting, but only 10% of community oncologists are having clinical trial discussions with their patients,” Bader said. “We remove the barrier of accessibility…70% of our patients are being treated in the community setting.”

Outside of patient care, TrialJectory may also facilitate progress in the pharmaceutical industry and with contract research organizations who are modeling trials and striving for greater patient inclusion.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors

April 5th 2024
Article

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Updated ASCO Guideline Issues Vaccine Recommendations in Cancer Populations

March 31st 2024
Article

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

FDA Clears IND for Novel Molecular Glue in Advanced Solid Tumors

March 29th 2024
Article

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.